RATIONALE: LY317615 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth and by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining LY317615 with capecitabine may kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of combining LY317615 with capecitabine in treating patients who have advanced solid tumors.

Condition	Treatment or Intervention	Phase
unspecified adult solid tumor, protocol specific	Drug: capecitabine  Drug: enzastaurin  Procedure: anti-cytokine therapy  Procedure: antiangiogenesis therapy  Procedure: biological response modifier therapy  Procedure: chemotherapy  Procedure: enzyme inhibitor therapy  Procedure: growth factor antagonist therapy	Phase I

Further Study Details: 

OBJECTIVES:

• Determine the maximum tolerated dose and the recommended phase II dose of LY317615 and capecitabine in patients with advanced solid tumors.
• Determine the safety profile of this regimen in these patients.
• Determine the pharmacokinetics of this regimen in these patients.
• Determine, preliminarily, the antitumor activity of this regimen in these patients.
• Determine the effects of LY317615 on potential angiogenic surrogate markers in these patients.

OUTLINE: This is a dose-escalation study.

Patients receive oral LY317615 daily on days 1-14 (course 1 only). Beginning with course 2, patients receive oral LY317615 daily on days 1-21 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of LY317615 and capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are treated at the recommended phase II dose.

Patients are followed at 30 days after the last dose of study drug.

PROJECTED ACCRUAL: A total of 12-36 patients will be accrued for this study.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed solid tumor that is refractory to standard therapy or for which no standard therapy exists
• Measurable or evaluable disease
• No known untreated or symptomatic CNS metastases
• No concurrent hematologic malignancies

PATIENT CHARACTERISTICS: Age

• 18 and over

Performance status

• ECOG 0-2

Life expectancy

• Not specified

Hematopoietic

• Absolute neutrophil count at least 1,500/mm^3
• Platelet count at least 100,000/mm^3
• Hemoglobin at least 9 g/dL (erythrocyte transfusions allowed)

Hepatic

• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• ALT and AST no greater than 2.5 times ULN (5 times ULN if liver metastases present)

Renal

• Creatinine clearance at least 50 mL/min
• Potassium at least 3.4 mEq/L
• Calcium at least 8.4 mg/dL
• Magnesium at least 1.2 mEq/L

Cardiovascular

• QTc interval no greater than 450 msec in males
• QTc interval no greater than 470 msec in females
• No other electrocardiogram abnormalities

Other

• Able to swallow capsules
• No gastrointestinal disorder that would interfere with oral drug absorption
• No serious concurrent systemic disorder
• No compliance issues that would preclude study
• No geographical conditions that would preclude study
• No active infection
• No prior hypersensitivity to any component of study drugs
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 3-6 months after study

PRIOR CONCURRENT THERAPY: Biologic therapy

• No concurrent immunotherapy
• No concurrent routine filgrastim (G-CSF)

Chemotherapy

• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
• No other concurrent chemotherapy

Endocrine therapy

• At least 4 weeks since prior anticancer hormonal therapy
• At least 6 weeks since prior bicalutamide
• At least 4 weeks since prior flutamide or nilutamide
• Concurrent luteinizing hormone-releasing hormone analog therapy (e.g., leuprolide or goserelin) allowed for patients with prostate cancer if started before study entry
• No other concurrent hormonal therapy

Radiotherapy

• At least 4 weeks since prior radiotherapy
• At least 2 weeks since prior palliative radiotherapy
• No concurrent radiotherapy (including palliative therapy)

Surgery

• Not specified

Other

• Recovered from prior therapy
• At least 4 weeks since prior investigational anticancer therapy
• At least 4 weeks since other prior anticancer therapy
• At least 30 days since prior experimental drugs
• No other concurrent experimental medications
• No other concurrent anticancer therapy

California
      Jonsson Comprehensive Cancer Center, UCLA, Los Angeles,  California,  90095-1781,  United States

Study chairs or principal investigators

Carolyn Britten, MD,  Principal Investigator,  Jonsson Comprehensive Cancer Center   

Study ID Numbers:  CDR0000258138; UCLA-0206061; LILLY-H6Q-MC-JCAH; NCI-G02-2132; NCT00052273
Record last reviewed:  February 2005
Last Updated:  February 8, 2005
Record first received:  January 24, 2003
ClinicalTrials.gov Identifier:  NCT00052273
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08